Thus, based on these findings, we propose that CD163 could be regarded as a biomarker for tumor progression and clinical outcomes in CRC, where a low expression may be seen in the early stages of development, and high expression may suggest invasion, metastasis, and a low survival rate. The gene discussed is CD163; the disease is neoplasm.